

SUPPLEMENTARY TABLES

Supplementary Table 1. Clinical parameters of human subjects.

| | Sarcopenia (N = 6) | Non-Sarcopenia (N = 13) | 95% CI of the difference | P-value | Reduced SMI (N = 11) | Control (N = 8) | 95% CI of the difference | p-value |
|----------------------------|-----------------------|----------------------------|--------------------------------|---------|-------------------------|--------------------|--------------------------------|----------|
| Age | 85.0 ± 8.6 | 83.8 ± 6.3 | -7.92 to 10.38 | 0.76 | 85.0 ± 8.6 | 83.8 ± 6.3 | -7.92 to 10.38 | 0.76 |
| Gender (Male; Female) | 1;5 | 6;7 | | | 2;9 | 5;3 | | |
| SMI (kg/m ²) | 5.0 ± 1.0 | 6.6 ± 1.2 | -2.77 to -0.48 | *0.01 | 5.2 ± 0.9 | 7.4 ± 0.8 | -2.99 to -1.31 | **0.0005 |
| Handgrip(kg) | 18.0 ± 4.0 | 23.0 ± 7.4 | -10.53 to 0.66 | 0.08 | 21.1 ± 5.4 | 23.4 ± 8.4 | -10.89 to 4.0 | 0.51 |
| TUG(sec.) | 23.5 ± 13.3 | 12.2 ± 6.5 | -2.68 to 25.26 | 0.1 | 18.1 ± 11.4 | 12.6 ± 8.3 | -4.10 to 14.95 | 0.27 |
| Walking Speed (m/sec.) | 1.07 ± 0.33 | 1.21 ± 0.40 | -0.61 to 0.33 | 0.53 | 1.09 ± 0.26 | 1.27 ± 0.48 | -0.57 to 0.21 | 0.37 |
| BMI(kg/m ²) | 20.0 ± 2.3 | 23.3 ± 3.6 | -6.15 to -0.33 | *0.03 | 20.7 ± 2.2 | 24.4 ± 4.0 | -7.20 to -0.26 | *0.04 |
| Fat mass (kg) | 12.7 ± 2.9 | 15.4 ± 5.7 | -7.98 to 2.59 | 0.19 | 13.4 ± 2.7 | 16.0 ± 7.2 | -7.60 to 2.33 | 0.35 |
| Calf circumference(cm) | 29.5 ± 4.1 | 33.5 ± 3.2 | -7.65 to -0.42 | *0.03 | 30.1 ± 3.1 | 35.3 ± 2.5 | -8.12 to -2.42 | **0.001 |
| MoCA-J | 18.2 ± 3.8 | 22.2 ± 4.8 | -8.40 to 0.42 | 0.07 | 20.5 ± 4.3 | 21.5 ± 5.6 | -6.17 to 4.08 | 0.66 |
| Systolic BP(mmHg) | 140.5 ± 10.4 | 136.5 ± 18.2 | -9.95 to 18.03 | 0.55 | 143.9 ± 13.7 | 129.3 ± 14.2 | 0.40 to 28.92 | *0.04 |
| Diastolic BP(mmHg) | 77.7 ± 6.8 | 77.3 ± 14.4 | -9.89 to 10.61 | 0.94 | 77.2 ± 13.7 | 77.8 ± 10.1 | -12.49 to 11.36 | 0.92 |
| iADL | 3.7 ± 3.1 | 2.0 ± 2.3 | -1.05 to 4.38 | 0.28 | 2.7 ± 2.7 | 2.3 ± 2.7 | -2.19 to 3.14 | 0.71 |
| CRE □ mg/dl □ | 0.61 ± 0.22 | 0.92 ± 0.28 | -0.57 to 0.06 | *0.02 | 0.68 ± 0.23 | 1.03 ± 0.25 | -0.59 to -0.11 | **0.008 |
| BUN □ mg/dl □ | 15.8 ± 4.8 | 19.7 ± 6.4 | -9.67 to 1.75 | 0.16 | 15.6 ± 3.8 | 22.4 ± 6.6 | -12.59 to -1.03 | *0.025 |
| CK □ U/L □ | 81.7 ± 24.6 | 124.4 ± 49.7 | -77.50 to -7.33 | *0.03 | 103.1 ± 54.2 | 121.3 ± 33.4 | -59.69 to 23.62 | 0.39 |
| AST (U/L □ | 20.8 ± 2.5 | 22.8 ± 4.8 | -5.46 to 1.59 | 0.26 | 22.9 ± 4.7 | 21.1 ± 3.6 | -2.20 to 5.77 | 0.36 |
| ALT (U/L □ | 12.5 ± 4.5 | 14.6 ± 5.4 | -7.27 to 3.04 | 0.39 | 13.8 ± 5.3 | 14.1 ± 5.3 | -5.53 to 4.92 | 0.90 |
| γGTP (U/L □ | 19.7 ± 5.9 | 32.3 ± 19.5 | -25.21 to -0.07 | *0.05 | 21.3 ± 5.4 | 38.0 ± 23.3 | -36.32 to 2.87 | 0.08 |
| HDL □ mg/dl □ | 77.0 ± 18.0 | 59.9 ± 17.4 | -2.67 to 36.82 | 0.08 | 66.5 ± 18.9 | 63.8 ± 20.2 | -16.82 to 22.23 | 0.77 |
| LDL □ mg/dl □ | 113.5 ± 17.5 | 119.8 ± 28.9 | -29.19 to 16.50 | 0.56 | 116.5 ± 21.6 | 119.6 ± 31.6 | -31.36 to 25.21 | 0.82 |
| Hba1c (%) | 5.6 ± 0.4 | 5.9 ± 0.5 | -0.72 to 0.12 | 0.15 | 5.7 ± 0.3 | 6.0 ± 0.6 | -0.81 to 0.22 | 0.20 |
| Alb □ g/dl □ | 3.9 ± 0.3 | 3.8 ± 0.2 | -0.25 to 0.42 | 0.57 | 3.9 ± 0.3 | 3.8 ± 0.3 | -0.18 to 0.34 | 0.53 |
| Glu □ mg/dl □ | 96.7 ± 11.5 | 100.4 ± 17.6 | -18.22 to 10.78 | 0.59 | 101.6 ± 18.5 | 95.9 ± 11.2 | -8.70 to 20.22 | 0.41 |
| TG □ mg/dl □ | 83.7 ± 53.9 | 134.4 ± 81.9 | -118.38 to 16.94 | 0.13 | 118.9 ± 73.6 | 117.6 ± 85.8 | -79.46 to 82.03 | 0.97 |
| WBC □ 10 ⁹ /L □ | 4.4 ± 1.0 | 5.5 ± 1.6 | -2.37 to 0.21 | 0.09 | 4.7 ± 1.2 | 5.7 ± 1.8 | -2.61 to 0.62 | 0.20 |
| RBC □ 10 ¹² /L) | 4.0 ± 0.2 | 4.2 ± 0.3 | -0.43 to 0.15 | 0.31 | 4.2 ± 0.3 | 4.2 ± 0.4 | -0.37 to 0.31 | 0.83 |
| Hb □ g/dl □ | 12.7 ± 0.7 | 12.8 ± 0.8 | -0.90 to 0.67 | 0.75 | 12.8 ± 0.7 | 12.7 ± 0.9 | -0.68 to 0.99 | 0.70 |
| HCT □ % □ | 39.3 ± 2.4 | 37.9 ± 2.9 | -1.29 to 4.17 | 0.27 | 38.6 ± 2.6 | 38.0 ± 3.1 | -2.27 to 3.48 | 0.66 |
| Plt □ 10 ⁹ /L □ | 238.2 ± 24.9 | 206 ± 53.9 | -5.99 to 70.32 | 0.09 | 217.5 ± 38.1 | 214.4 ± 62.9 | -52.19 to 58.34 | 0.90 |

In addition to clinical features derived from sarcopenia diagnosis, 19 participants were statistically analyzed by SMI. Comparison between the sarcopenia and non-sarcopenia groups detected significant decreases in SMI (5.0 ± 1.0 vs 6.6 ± 1.2 kg/m², $p < 0.05$), Body Mass Index (BMI) (20.0 ± 2.3 U/L vs 23.3 ± 3.6 kg/m², $p < 0.05$), serum creatinine (0.61 ± 0.22 vs 0.92 ± 0.28 mg/dl, $p < 0.05$), serum creatine kinase (CK) (81.7 ± 24.6 vs 124.4 ± 49.7 U/L, $p < 0.05$) and serum γGTP (19.7 ± 5.9 vs 32.3 ± 19.5 U/L, $p < 0.05$) in sarcopenia. A comparison between decreased and normal SMI groups detected significant decreases in SMI (5.2 ± 0.9 vs 7.4 ± 0.8 kg/m², $p < 0.01$, BMI (20.7 ± 2.2 vs 24.4 ± 4.0 kg/m², $p < 0.05$), serum creatinine (0.68 ± 0.23 vs 1.03 ± 0.25 mg/dl, $p < 0.01$) and serum BUN (15.6 ± 3.8 vs 22.4 ± 6.6 mg/dl, $p < 0.05$) and a significant increase in systolic blood pressure (143.9 ± 13.7 vs 129.3 ± 14.2 mmHG, $p < 0.05$). Asterisks indicate significant differences (* $p < 0.05$). Asterisks indicate significant differences (** $p < 0.01$). Abbreviation: SMI: skeletal muscle mass index; MoCA-J: Japanese version of Montreal Cognitive Assessment; TUG: Timed up and go test; BMI: Body mass index; BP: Blood pressure; CRE: creatinine; BUN, Blood urea nitrogen; CK: creatine kinase; HCT: hematocrit; CI: Confidence Interval.

Supplementary Table 2. List of 22 metabolites involved in sarcopenia.

| Parameters | Peak area (10 ⁶ AU) | | T test | |
|--------------------------|--------------------------------|-----------------|--------------------|---------|
| | Sarcopenia | Non-sarcopenia | 95% CI of the dif. | p-value |
| | (N = 6) | (N = 13) | | |
| Acetyl-carnitine | 337.73 ± 76.94 | 433.23 ± 99.79 | -186.23 to -4.77 | *0.040 |
| Dimethyl-proline | 186.23 ± 91.05 | 313.38 ± 102.26 | -230.09 to -24.20 | *0.020 |
| Phenylalanine | 225.19 ± 55.70 | 287.35 ± 40.46 | -121.27 to -3.07 | *0.042 |
| Dimethyl-arginine | 38.92 ± 4.67 | 50.22 ± 13.03 | -19.94 to -2.66 | *0.013 |
| N1-Methyl-histidine | 21.75 ± 8.25 | 37.39 ± 12.08 | -25.82 to -5.44 | **0.005 |
| Isovaleryl-carnitine | 14.24 ± 3.85 | 20.57 ± 7.7 | -11.95 to -0.71 | *0.033 |
| Aspartate ^(↑) | 22.91 ± 5.65 | 13.64 ± 7.84 | 2.44 to 16.09 | *0.011 |
| myo-Inositol | 13.95 ± 1.58 | 20.30 ± 7.43 | -10.98 to -1.72 | *0.011 |
| Creatinine | 15.60 ± 4.82 | 21.48 ± 6.64 | -11.70 to -0.08 | *0.047 |
| Pantothenate | 10.14 ± 3.09 | 17.20 ± 8.03 | -12.47 to -1.65 | *0.013 |
| Hypoxanthine | 4.11 ± 1.36 | 7.58 ± 4.95 | -6.62 to -0.31 | *0.033 |
| Dimethyl-guanosine | 2.50 ± 0.74 | 3.95 ± 0.81 | -2.29 to -0.62 | **0.003 |
| N1-Methyl-adenosine | 2.36 ± 1.07 | 3.64 ± 1.08 | -2.47 to -0.10 | *0.036 |
| 2-Oxoglutarate | 2.01 ± 0.49 | 3.01 ± 1.1 | -1.76 to -0.23 | *0.018 |
| Pentose-phosphate | 2.13 ± 0.24 | 2.71 ± 0.75 | -1.07 to -0.09 | *0.022 |
| Succinate | 1.33 ± 0.18 | 1.74 ± 0.45 | -0.71 to -0.10 | *0.012 |
| N-Acetyl-glutamate | 0.42 ± 0.14 | 0.58 ± 0.12 | -0.31 to -0.01 | *0.037 |
| Quinolinic acid | 0.26 ± 0.14 | 0.50 ± 0.24 | -0.43 to -0.06 | *0.013 |
| 4-Guanidinobutanoate | 0.16 ± 0.06 | 0.55 ± 0.60 | -0.76 to -0.03 | *0.035 |
| N1-Methyl-guanosine | 0.21 ± 0.09 | 0.32 ± 0.10 | -0.21 to -0.01 | *0.038 |
| Trimethyl-tyrosine | 0.05 ± 0.04 | 0.17 ± 0.17 | -0.23 to -0.02 | *0.027 |
| cis-Aconitate | 0.05 ± 0.02 | 0.12 ± 0.05 | -0.10 to -0.04 | **0.000 |

Metabolite peak area. High > 10⁸ AU. Medium 10⁷–10⁸ AU. Low < 10⁷ AU. 21 sarcopenia markers (acetyl-carnitine, dimethyl-proline, phenylalanine, dimethyl-arginine, N1-methyl-histidine, isovaleryl-carnitine, myo-inositol, creatinine, pantothenate, hypoxanthine, dimethyl-guanosine, N1-methyl-adenosine, 2-oxoglutarate, pentose-phosphate, succinate, N-acetyl-glutamate, quinolinic acid, 4-guanidinobutanoate, N1-methyl-guanosine, trimethyl-tyrosine, and cis-aconitate) decreased significantly. However, aspartate increased significantly in sarcopenia. Abbreviations: SMI: skeletal muscle index; CI: Confidence Interval. (↑) indicates upregulated metabolite in sarcopenia. Asterisks indicate significant differences (*p < 0.05). Asterisks indicate significant differences (**p < 0.01).

Supplementary Table 3. List of ten metabolites involved in muscle mass.

| | Peak area (10 ⁶ AU) | | T test | |
|----------------------|--------------------------------|----------------|--------------------|---------|
| | Decreased SMI | Normal SMI | 95% CI of the dif. | p-value |
| | (N = 11) | (N = 8) | | |
| Urate | 95.24 ± 21.23 | 114.54 ± 1.64 | -38.18 to -0.41 | *0.046 |
| Butyro-betaine | 88.02 ± 19.93 | 108.91 ± 19.46 | -40.32 to -1.47 | *0.037 |
| Dimethyl-arginine | 40.23 ± 11.17 | 55.48 ± 7.04 | -24.09 to -6.40 | **0.002 |
| N1-Methyl-histidine | 24.73 ± 9.48 | 43.07 ± 9.55 | -27.77 to -8.93 | **0.001 |
| Isovaleryl-carnitine | 14.47 ± 3.12 | 24.21 ± 7.76 | -16.34 to -3.14 | **0.009 |
| Creatinine | 16.89 ± 6.31 | 23.38 ± 5.27 | -12.12 to -0.86 | *0.026 |
| Hippurate | 12.92 ± 8.00 | 26.70 ± 13.19 | -25.37 to -2.19 | *0.020 |
| Dimethyl-guanosine | 2.98 ± 0.92 | 4.20 ± 0.74 | -2.03 to -0.41 | **0.005 |
| 2-Oxoglutarate | 2.15 ± 0.53 | 3.45 ± 1.14 | -2.27 to -0.32 | *0.014 |
| cis-Aconitate | 0.07 ± 0.04 | 0.14 ± 0.05 | -0.11 to -0.27 | **0.004 |

Metabolite peak area. High > 10⁸ AU, Medium 10⁷–10⁸ AU, Low < 10⁷ AU. 10 metabolites (urate, butyro-betaine, dimethyl-arginine, N1-methyl-histidine, isovaleryl-carnitine, creatinine, hippurate, dimethyl-guanosine, 2-oxoglutarate, cis-aconitate) decreased significantly in sarcopenia. Abbreviations: SMI: skeletal muscle index; CI: Confidence Interval. Asterisks indicate significant differences (**p* < 0.05). Asterisks indicate significant differences (***p* < 0.01).

Supplementary Table 4. Correlation analysis between 25 sarcopenia-related markers and SMI or EFS.

| Parameters | SMI | | | EFS | | |
|--------------------------|-------|-----------------|---------|-------|----------------|---------|
| | R | 95% CI | p value | R | 95% CI | p value |
| Isovaleryl-carnitine | 0.70 | 0.37 to 0.88 | **0.001 | -0.55 | -0.80 to -0.12 | *0.015 |
| Urate | 0.58 | 0.18 to 0.82 | **0.008 | -0.54 | 0.10 to 0.79 | *0.02 |
| Hippurate | 0.60 | 0.21 to 0.83 | **0.006 | -0.46 | -0.76 to -0.01 | *0.05 |
| Phenylalanine | 0.40 | -0.07 to 0.72 | 0.09 | -0.45 | -0.75 to 0.00 | 0.05 |
| Butyro-betaine | 0.5 | 0.06 to 0.78 | *0.029 | -0.44 | -0.75 to 0.01 | 0.05 |
| Acetyl-carnitine | 0.55 | 0.12 to 0.80 | *0.02 | -0.43 | -0.74 to 0.03 | 0.06 |
| N1-Methyl-guanosine | 0.65 | 0.27 to 0.85 | **0.003 | -0.39 | -0.71 to 0.08 | 0.10 |
| Pantothenate | 0.62 | 0.23 to 0.84 | **0.005 | -0.36 | -0.70 to 0.11 | 0.13 |
| N1-Methyl-histidine | 0.58 | 0.17 to 0.82 | **0.009 | -0.3 | -0.66 to 0.18 | 0.22 |
| Hypoxanthine | 0.52 | 0.09 to 0.79 | *0.02 | -0.29 | -0.65 to 0.18 | 0.22 |
| Dimethyl-guanosine | 0.62 | 0.23 to 0.84 | **0.005 | -0.28 | -0.65 to 0.20 | 0.25 |
| Dimethyl-arginine | 0.55 | 0.12 to 0.80 | *0.02 | -0.27 | -0.64 to 0.20 | 0.26 |
| Creatinine | 0.69 | 0.35 to 0.87 | **0.001 | -0.25 | -0.63 to 0.23 | 0.31 |
| Dimethyl-proline | 0.24 | -0.24 to 0.63 | 0.32 | -0.25 | -0.63 to 0.23 | 0.31 |
| N-Acetyl-glutamate | 0.41 | -0.05 to 0.73 | 0.08 | -0.21 | -0.60 to 0.26 | 0.38 |
| Quinolinic acid | 0.36 | -0.11 to 0.70 | 0.13 | -0.19 | -0.59 to 0.28 | 0.44 |
| 2-Oxoglutarate | 0.65 | 0.27 to 0.85 | **0.003 | -0.17 | -0.58 to 0.31 | 0.49 |
| Trimethyl-tyrosine | 0.28 | -0.20 to 0.65 | 0.24 | -0.17 | -0.58 to 0.30 | 0.47 |
| Aspartate ⁽¹⁾ | -0.45 | -0.75 to -0.001 | 0.05 | -0.17 | -0.30 to 0.58 | 0.48 |
| cis-Aconitate | 0.57 | 0.16 to 0.82 | *0.01 | -0.16 | -0.57 to 0.32 | 0.52 |
| Succinate | 0.59 | 0.19 to 0.82 | **0.008 | -0.12 | -0.54 to 0.36 | 0.63 |
| Pentose-phosphate | 0.31 | -0.17 to 0.67 | 0.20 | -0.11 | -0.53 to 0.36 | 0.65 |
| 4-Guanidinobutanoate | 0.20 | -0.27 to 0.60 | 0.41 | -0.1 | -0.53 to 0.37 | 0.68 |
| N1-Methyl-adenosine | 0.37 | -0.10 to 0.71 | 0.12 | -0.07 | -0.52 to 0.40 | 0.76 |
| myo-Inositol | 0.52 | 0.09 to 0.79 | *0.02 | -0.04 | -0.48 to 0.42 | 0.88 |

Metabolite peak area. High > 10⁸ AU. Medium 10⁷–10⁸ AU. Low < 10⁷ AU. Metabolites are ordered according to its correlation coefficient to EFS. Abbreviations: SMI: skeletal muscle index; Pearson: Pearson's correlation coefficient between a metabolite and SMI; CI: Confidence Interval; EFS: Edmonton frail scale. Asterisks indicate correlation (**p* < 0.05). Asterisks indicate correlation (***p* < 0.01).

Supplementary Table 5. Correlation analysis between 22 frailty-related markers and SMI or EFS.

| | SMI | | | EFS | | |
|-------------------------------|-------|---------------|---------|-------|----------------|---------|
| | R | 95% CI | p value | R | 95% CI | p value |
| <i>Isovaleryl-carnitine</i> | 0.70 | 0.37 to 0.88 | **0.001 | -0.54 | -0.80 to -0.12 | *0.015 |
| <i>Acetyl-carnosine</i> | 0.69 | 0.35 to 0.87 | **0.001 | -0.51 | 0.07 to 0.78 | *0.03 |
| <i>Hippurate</i> | 0.60 | 0.21 to 0.83 | **0.006 | -0.46 | 0.01 to 0.76 | *0.05 |
| Urate | 0.58 | 0.18 to 0.82 | **0.009 | -0.54 | 0.11 to 0.80 | *0.02 |
| <i>1,5-anhydroglucitol</i> | 0.52 | 0.08 to 0.79 | *0.02 | -0.56 | 0.14 to 0.80 | *0.01 |
| Proline | 0.49 | 0.05 to 0.77 | *0.03 | -0.54 | 0.11 to 0.80 | *0.02 |
| <i>Methionine</i> | 0.46 | 0.01 to 0.76 | *0.046 | -0.56 | 0.14 to 0.80 | *0.01 |
| <i>Leucine</i> | 0.46 | 0.01 to 0.75 | *0.046 | -0.46 | 0.01 to 0.75 | *0.04 |
| <i>N3-methyl-histidine</i> | 0.45 | -0.01 to 0.74 | 0.05 | -0.19 | -0.59 to 0.29 | 0.43 |
| <i>Trimethyl-histidine</i> | 0.44 | -0.01 to 0.75 | 0.057 | -0.39 | -0.08 to 0.71 | 0.10 |
| <i>Isoleucine</i> | 0.42 | -0.04 to 0.74 | 0.07 | -0.45 | 0.14 to 0.80 | *0.04 |
| Tryptophan | 0.37 | -0.09 to 0.71 | 0.12 | -0.57 | 0.15 to 0.82 | *0.01 |
| Arginine | 0.36 | -0.11 to 0.70 | 0.13 | -0.32 | -0.15 to 0.67 | 0.17 |
| Ergothioneine | 0.33 | -0.14 to 0.69 | 0.16 | -0.45 | 0.01 to 0.75 | 0.05 |
| <i>Adenine</i> | 0.23 | -0.25 to 0.62 | 0.34 | -0.45 | -0.001 to 0.75 | 0.05 |
| <i>S-methyl-ergothioneine</i> | 0.22 | -0.26 to 0.61 | 0.37 | -0.51 | 0.07 to 0.78 | *0.02 |
| <i>Ophthalmic acid</i> | 0.14 | -0.34 to 0.56 | 0.56 | -0.41 | -0.06 to 0.73 | 0.08 |
| <i>2-ketobutyrate</i> | 0.14 | -0.33 to 0.56 | 0.56 | -0.29 | -0.19 to 0.66 | 0.24 |
| <i>UDP-glucose (↑)</i> | 0.04 | -0.41 to 0.49 | 0.86 | -0.12 | -0.55 to 0.34 | 0.60 |
| Creatine (↑) | -0.08 | -0.51 to 0.38 | 0.73 | 0.44 | -0.74 to 0.02 | 0.06 |
| <i>N-acetyl-aspartate (↑)</i> | -0.09 | -0.52 to 0.38 | 0.71 | 0.16 | -0.32 to 0.57 | 0.51 |
| <i>UDP-glucuronate (↑)</i> | -0.15 | -0.56 to 0.32 | 0.54 | 0.47 | -0.76 to -0.02 | *0.04 |

Metabolite peak area. High > 10⁸ AU. Medium 10⁷–10⁸ AU. Low < 10⁷ AU. Metabolites are ordered according to its correlation coefficient to SMI. Abbreviations: SMI: skeletal muscle index; Pearson: Pearson's correlation coefficient between a metabolite and SMI; CI: Confidence Interval. Asterisks indicate correlation (*p < 0.05). Asterisks indicate correlation (**p < 0.01).